EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference

EDAP TMS SA, a frontrunner in robotic energy-based therapies, is set to present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 18, 2026. The company’s Chief Executive Officer, Ryan Rhodes, along with Chief Financial Officer, Ken Mobeck, will deliver a presentation and conduct one-on-one investor meetings during the event. Scheduled from 12:00 to 12:30 PM ET, the presentation will take place in a virtual format, with a live webcast accessible to interested parties.

EDAP specializes in developing minimally invasive medical devices, leveraging advanced ultrasound technology for various medical conditions. The company is particularly notable for its Focal One® system, a cutting-edge prostate focal therapy that allows urologists to perform treatments with precision and control. Having achieved recognition in Europe and the U.S., Focal One® is poised for expansion into additional medical areas beyond prostate cancer, highlighting the company's commitment to advancing healthcare technologies.

Investors and stakeholders can participate in the conference virtually through the webcast, which will also be archived for later access on the company’s investor section of its website. This event represents a key opportunity for EDAP to engage with investors and showcase its innovative solutions in the healthcare field.

As the company continues to pioneer developments in non-invasive therapies, EDAP TMS SA solidifies its prominent role in the MedTech landscape, providing critical updates to its investor base and enhancing its visibility on impactful healthcare advancements.

For more detailed information about EDAP and its products, visit [EDAP's official website](https://focalone.com/). Investors can direct any inquiries to the company's investor relations team via email.

As EDAP TMS SA (Nasdaq: EDAP) prepares to present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 18, 2026, investors should closely monitor this event. The company, a recognized leader in robotic energy-based therapies, continues to innovate within the healthcare sector, specifically in the realm of minimally invasive medical devices utilizing ultrasound technology.

During the conference, CEO Ryan Rhodes and CFO Ken Mobeck will not only present the company's advancements but also engage in one-on-one investor meetings, providing a valuable opportunity for meaningful interactions that could yield insights into EDAP's strategic direction, financial performance, and future growth prospects.

EDAP’s flagship product, the Focal One®, has gained traction as a leading prostate focal therapy, capturing interest for its potential applications beyond prostate cancer. This positioning could be critical, particularly as the medical community increasingly favors non-invasive treatment alternatives. The company's commitment to combining advanced imaging, robotics, and precise non-invasive energy delivery will likely be a focal point of the presentation and could influence investor sentiment.

Investors should pay attention to the details shared during the conference regarding regulatory updates, commercial strategies, and upcoming clinical trials related to the Focal One and any new product developments. Moreover, understanding the competitive landscape and EDAP's market position will be pivotal, especially as telemedicine and robotic health solutions are becoming more prevalent.

Given the healthcare sector's robust momentum post-pandemic, along with EDAP’s innovative solutions, there may be bullish opportunities if the company can effectively communicate its roadmap and continue to capture market share. Investors should consider utilizing the conference as an entry point to reassess their positions in EDAP, particularly if new growth signals emerge.